Latest France News

Orora Limited announces a leadership transition in its Global Glass division, with Emmanuel Ladent set to succeed Jean Marc Arrambourg as President by year-end 2025.

Microba Life Sciences reveals preliminary data from over 4,600 MetaXplore GI Plus tests showing significant clinical findings in the majority of patients, with two-thirds reporting symptom improvements following test-guided care.

National Australia Bank has announced a fully franked ordinary dividend of AUD 0.85 per share for the half-year ending March 2025, alongside Dividend Reinvestment and Bonus Security Plans offering shareholders multiple currency payment options.

UNITH Ltd reports a 9.3% rise in Q3 FY25 cash receipts driven by its B2C subscription surge and a landmark pharmaceutical contract, alongside strategic platform upgrades and leadership changes.

Little Green Pharma reported a robust 40% revenue increase for FY25, driven by strong European sales and the strategic acquisition of Health House. The company also advanced clinical research and secured new therapy funding, positioning itself for continued growth.

Gas2Grid Limited moves closer to securing a new service contract in the Philippines while appealing a significant legal claim in France, all under the pressure of an impending ASX suspension deadline.

Titomic Limited advances its strategic U.S. footprint with a new Huntsville facility set to open in June 2025, securing major defense collaborations and expanding commercial momentum in additive manufacturing.

Apollo Minerals reports completion of Phase 2 drilling at its Salanie Gold Project with promising high-grade results, alongside strategic funding and ongoing exploration in Gabon, Serbia, and France.

Medical Developments International reported a robust Q3 FY25 with $8.9 million revenue and $1.7 million operating cashflow, driven by strong Penthrox demand and pricing. New distribution agreements in France and Switzerland position the company for further European expansion.

BrainChip Holdings advanced its neuromorphic AI technology through significant contracts with the Swedish National Space Agency and the U.S. Air Force, while exploring a potential redomiciling to the US. The company reported steady cash outflows and ongoing strategic partnerships.

Cochlear Limited posted a 6% increase in HY25 sales revenue driven by strong implant sales but anticipates FY25 profits at the lower end of guidance due to declining services revenue and rising cloud investments.

Cochlear Limited has reported a robust half-year performance with a 7% increase in underlying net profit and an 8% rise in interim dividends, driven by strong sales in cochlear and acoustic implants despite a decline in services revenue.